泰恩康获“ESG新锐金牛奖二十强”奖项 创新驱动可持续发展

Core Viewpoint - The company TianKang has been recognized for its outstanding practices in ESG (Environmental, Social, and Governance) and rapid growth, winning the "ESG New Star Golden Bull Award Top 20" at the 2025 Golden Bull Enterprise Sustainable Development Forum [1] Group 1: ESG Practices - TianKang focuses on the pharmaceutical health sector, driving development through "innovation + responsibility" [2] - The company optimizes production processes and implements green manufacturing principles, ensuring environmental standards from raw material procurement to waste disposal, aiding the pharmaceutical industry's low-carbon transition [2] - In the social value dimension, TianKang emphasizes research and development in three core areas: sexual health, ophthalmology, and gastrointestinal medications, addressing clinical needs through high-intensity R&D investment [2] Group 2: R&D and Innovation - The company has established a comprehensive independent R&D system, forming a strong product development team with a "pyramid" R&D strategy, focusing on generic drug development as the base, followed by improved chemical drugs and biological drugs, with innovative drug research at the peak [2] - R&D investment as a percentage of revenue increased from 6.90% in 2022 to 21.96% in 2024, with 20 drug registration applications accepted, indicating a robust R&D pipeline [2] - The innovative drug CKBA is expected to fill a gap in domestic vitiligo treatment, targeting a market worth over 10 billion [2] Group 3: Corporate Governance and Future Strategy - TianKang has built a modern corporate governance structure, with management committed to long-termism and no plans for share reduction post-lockup, demonstrating confidence in development [3] - The company is creating a global pharmaceutical innovation sharing platform, combining internal growth with external collaborations to accelerate first-in-class innovative drug development, with projects like CKBA ointment progressing well [3] - TianKang aims to deepen the integration of ESG into its corporate development strategy, enhancing its commitment to social responsibility and product quality while increasing its focus on innovative drug development [3]